Kornimate/medical-research-clean huggingface dataset:
brain state-dependent pcms in chronic stroke

Conditions: Stroke

Summary: after stroke, people often have difficulty using their hands. combined brain and nerve stimulation can strengthen the neural pathways that control hand function. in this study, we will deliver combined brain and nerve stimulation during specific time windows that increase activation of neural pathways underlying hand function. we will compare the effects of combined brain and nerve stimulation during these optimal time windows to the effects of combined brain and nerve stimulation applied during random time windows on post-stroke hand function.


Eligibility criteria:
inclusion criteria: * history of stroke \> 6 months ago * presence of residual upper extremity hemiparesis * willingness to participate * ability to provide informed consent * upper extremity fugl-meyer score \< 66 * mini mental state exam score \> 24 * discernible and reliable motor-evoked potential (mep) elicited following single-pulse tms to the lesioned hemisphere exclusion criteria: * history of neurological disease other than stroke * presence of contraindications to transcranial magnetic stimulation (tms) or peripheral nerve stimulation (pns), including: history of adverse reactions to tms or pns metal in head, eyes, neck, chest/trunk, or arms, including but not limited to shrapnel, surgical clips, fragments from metalworking, fragments from welding, implanted device, history of frequent and severe headaches or migraines, immediate family history of seizure or epilepsy, personal history of seizure or epilepsy, current, suspected, or planned pregnancy, current or recent (within the last 3 months) use of medications acting on the central nervous system other than selective serotonin reuptake inhibitors (ssris), including but not limited to antipsychotic drugs, benzodiazepines, prescription stimulants. * upper extremity fugl-meyer score ≥ 66 (66 is the maximum on this scale) * mini mental state exam score \<= 24 * no discernible and reliable mep elicited following single-pulse tms to the lesioned hemisphere

Keywords: chronic, movement
analysis of respiration-induced deformities of the visceral and renal arteries before and after stenting

Conditions: Complex Aortic Aneurysms

Summary: fenestrated stents are used for the management of complex juxta-renal, para-renal or thoracoabdominal aneurysms in patients with high surgical risk and/or contraindicated for open surgery. these endovascular techniques have demonstrated their safety and efficacy, however, long-term follow-up ct scans remain essential for the detection of complications such as endo-leaks and restenosis/thrombosis of visceral and renal stents. the respiratory cycle might induce changes in the geometry and deformations of visceral and renal stents after complex aortic procedures. these could be detected by an adapted ct scan analysis by deep inhalation and deep exhalation acquisition carried out pre-operatively and post-operatively for monitoring of these same stents and screening for complications.


Eligibility criteria:
inclusion criteria: * no contre indication for coroscanner exclusion criteria: * pregnant woman * allergy to iodinated contrast media * vulnerable people
the jordan study for end-stage renal disease subjects

Conditions: End Stage Renal Disease

Summary: to compare the alio device to blood draws.

eligible subjects who have signed a consent form will be asked to wear the alio device at specified location(s) for up to four regularly scheduled dialysis sessions. the device will be placed and worn throughout the entire session. subjects will have blood draws that will be used to compare to device metrics. additional vitals and monitoring may happen throughout this study.

Eligibility criteria:
inclusion criteria: * 18 and older * maintenance dialysis for esrd via avf/avg in an arm location for at least 6 months * written informed consent * able to wear the smartpatch as instructed and follow study protocols exclusion criteria: * skin near the proximity of patch placement is swollen, infected and/or inflamed * pregnancy * serious medical condition which in the opinion of the investigator may adversely affect the safety of the subject or the device being evaluated * avf/avg in a non-arm location * participants with novel indications for their avg (ie. hero grafts) * participation in any other clinical trials that could affect the quality of study data
a pilot study using placenta derived decidual stromal cells for hemorrhagic cystitis

Conditions: Hemorrhagic Cystitis

Summary: the purpose of this study is to evaluate the safety and efficacy using placenta derived decidual stromal cell therapy for hemorrhagic cystitis after allogeneic hematopoietic cell transplantation. it is hypothesized that the decidual stromal cell therapy is safe to infuse and that they have a positive clinical effect.

patients with grade 2-4 hemorrhagic cystitis will receive decidual stromal cell therapy at approximately 1-2x10\^6 cells/kg once or at weekly intervals dependent on clinical effect.

Eligibility criteria:
inclusion criteria: * hemorrhagic cystitis grade 2-4 exclusion criteria: * urinary urge without macroscopic hematuria or clots

Keywords: stem cell transplantation decidual stromal cells
comparison of hepatus and fibroscan for evaluation of fibrosis and steatosis

Conditions: Chronic Hepatitis b; Non-Alcoholic Fatty Liver Disease

Summary: totals of 400 chronic hepatitis b or non-alcoholic fatty liver disease (nafld) patients with or without cirrhosis will be enrolled. patients' clinical characteristics, including alanine aminotransferase, aspartic aminotransferase, total bilirubin, direct bilirubin, indirect bilirubin, triglyceride and total cholesterol, hepatitis b surface antigen, steatosis, and liver stiffness measurement will be collected. the consistence of liver fibrosis and steatosis assessment between hepatus and fibroscan will be evaluated in this study.


Eligibility criteria:
inclusion criteria: * patients with or without cirrhosis diagnose as chronic hepatitis b or non-alcoholic fatty liver disease; * age above 18 years; * signature of informed consent. exclusion criteria: * patients with hcv and/or other viral hepatitis, autoimmune liver disease, alcoholic liver disease, genetic liver disease or other chronic liver diseases; * patients with decompensated cirrhosis; * patients with serum total bilirubin level higher than 51 umol/l; * patients with liver malignant lesion, hemangiomas, giant liver cysts and other liver lesions; * patients with hiv infections; * patients after liver transplantation or tips; * pregnant women; * patients with budd-chiari syndrome, chronic congestive heart failure, constrictive pericarditis or other liver congestion lesions.

Keywords: chronic hepatitis b non-alcoholic fatty liver disease liver fibrosis/cirrhosis steatosis
thymoglobulin induction in kidney transplant recipients

Conditions: Kidney Transplantation; Ischemia-Reperfusion Injury

Summary: the purpose of this study is to determine if anti-thymocyte globulin (thymoglobuline) administration in the kidney transplant recipient is able to reduce the amount of damage that kidneys transplanted from deceased donors sustains on reperfusion.

the increasing disparity between organ availability and the number of patients on waiting list for a transplant has led to different strategies to improve half life of all transplants. one such method is to reduce the amount of damage the organ sustains during the period of preservation and reperfusion in the recipient. thymoglobulin, an anti-lymphocyte antibody has been shown to have the ability to reduce this damage in experimental studies. this study aims to ascertain the role of thymoglobulin in kidney transplants from donors after cardiac death, the type of kidney transplants at highest risk of sustaining injury during preservation. the study will involve comparison with conventional immunosuppressant therapy, comparison between thymoglobulin administered in different doses, and observation of the patterns of blood cell repopulation (lymphocytes mainly) in the first year following kidney transplantation.

Eligibility criteria:
inclusion criteria: * participant is willing and able to give informed consent for participation in the study * male or female, aged 18 years or above * recipient of dcd kidney transplant * female participants of child bearing potential and male participants whose partner is of child bearing potential must be willing to ensure that they or their partner use effective contraception during the first 12 months of the study * able (in the investigators opinion) and willing to comply with all study requirements * willing to allow his or her general practitioner and consultant, if appropriate, to be notified of participation in the study exclusion criteria: * the participant may not enter the study if any of the following apply: * failure of either recipient of a pair of kidneys to give consent * female participant who is pregnant, lactating or planning pregnancy during the course of the study. * history of specific viral infection that would contraindicate depleting antibody therapy e.g. hepatitis b\&c, hiv * significant hepatic impairment-.i.e. values 3 times upper limit of normal (unless this is usual for the subject) * any other significant disease or disorder which, in the opinion of the investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study * participants who have participated in another research study involving an investigational product in the previous 12 weeks * previous administration of thymoglobuline * patients with functioning non-renal transplants and on immunosuppression * the patient is not suitable, in the opinion of the investigator, to take part in the trial

Keywords: kidney transplantation donation after cardiac death ischemia-reperfusion injury thymoglobulin steroid avoidance lymphocyte
clinical evaluation of neoadjuvant chemotherapy for primary malignant sarcomas that originate in bone

Conditions: Clinical Response; Histopathological Response; Prognosis

Summary: for bone lesions treated with chemotherapy or targeted therapy, particularly for sarcomas that originate in bones, response evaluation criteria in solid tumors (recist) 1.1 is spurious because bone lesions are typically located in irregularly shaped bones, are difficult to measure accurately, and usually respond more slowly to treatment than soft tissue lesions. positron emission tomography response criteria in solid tumors (percist) allows for response to be measured in the absence of anatomic changes through assessment of metabolic activity. it does not, however, account for morphologic changes. this study evaluated whether clinical imaging findings of sarcomas after preoperative chemotherapy correlate with tumor responses by pathological evaluation using the rate of necrosis to develop reliable and quantitative clinical response criteria.

we reviewed a total of 190 primary lesions by clinical imaging, including x-ray, computed tomography (ct), magnetic resonance imaging, and bone scan or pet/ct in patients who received neoadjuvant chemotherapy. all patients had curative surgery of those lesions at peking university people's hospital or peking university shougang hospital. pathological evaluation was completed by determination of the tumor necrosis rate following huvos' description. we also performed statistical diversity analysis for different pathological groups and generated receiver operating characteristic curves (roc) to define the thresholds to distinguish different pathological groups.

Eligibility criteria:
inclusion criteria: * (1) patients with high-grade sarcoma that originated in bone and confirmed histologically; * (2) patients who routinely received neoadjuvant chemotherapy according to peking university people's hospital chemo-protocols (pkuph-os and pkuph-es); * (3) patients who had primary tumor resection with assessment of histological response according to literatures; * (4) patients who had intact pre- and post-neoadjuvant chemotherapy imaging, which included x-ray, contrasted computed tomography (ct), and magnetic resonance imaging (mri) of the primary lesions as well as chest ct (with each layer ≤5 mm), bone scan, or \[18f\]2-fluoro-2-deoxy-d-glucose-positron emission tomography (fdg-pet); * (5) patients for whom follow-up information and evaluation after chemotherapy were available. exclusion criteria: * patients with incomplete medical materials; * patients without surgery of the primary site/ without pathological analysis of the specimens;

Keywords: osteosarcoma ewing sarcoma clinical evaluation pathological evaluation chemotherapy targeted therapy
population-based modeling of cholesterol lowering in the united states

Conditions: Cardiovascular Diseases; Coronary Heart Disease Risk Reduction; Heart Diseases; Coronary Disease; Hypercholesterolemia

Summary: to evaluate the cost-effectiveness of cholesterol-lowering strategies in the united states population. the study used the coronary heart disease (chd) policy model, a state-transition computer simulation model used to obtain forecasts of the public health impact and economic cost of chd in the united states population.

background: the study was part of an institute-initiated request for applications (rfa) titled "cost-effective strategies of cholesterol-lowering" released by the nhlbi in 1990. the rfa was stimulated by the controversy concerning costs and cost-effectiveness that followed the 1987 report of the national cholesterol education program (ncep) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. the rfa was intended to support a broad and thorough quantitative exploration of the potential health benefits and costs of cholesterol-lowering from multiple perspectives. design narrative: the study added to the chd policy model the capability to model the consequences of reductions in ldl cholesterol and increases in hdl/ldl ratios in the united states population. the chd policy model was used for several studies, including: to compare the implications of using alternative epidemiologic studies as the basis for estimating the association between cholesterol levels and chd risk; to derive cutting points for initiating cholesterol reduction, specific to age, sex, and chd risk factors, and based on cost-effectiveness criteria; to compare the cost-effectiveness of specific targeted and population-wide strategies for cholesterol reduction; to incorporate the effects of treatments on quality of life, including both adverse effects of cholesterol-lowering drugs and reductions in chd morbid events; and finally, to perform a cost-effectiveness analysis of cholesterol screening, incorporating costs of screening, effects of measurement error on misclassification of patients, and variations in individual cholesterol levels over time. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria
effect of herring oil concentrate on ldl cholesterol concentration in adults

Conditions: High Cholesterol

Summary: high cholesterol concentration is a major risk factor for cardiovascular disease (cvd), and consumption of fish has been associated with a lower cvd risk in several studies. the beneficial health effects of consuming fish have traditionally been ascribed to the long-chain pufa (lc-pufa) epa (c20:5n-3) and dha (c22:6n-3), although consumption of fish oils or concentrates with high epa and dha contents does not affect the cholesterol concentration in humans and lowers the cholesterol concentration in rats and mice only when given in very high doses. fish oils contain a plethora of fatty acids besides epa and dha, and in recent years, increased focus has been on the long-chain mufa (lc-mufa) cetoleic acid (c22:1n-11). cetoleic acid is found in high amounts in oils from certain fish species such as herring, which has relatively low contents of both epa and dha. the investigators have recently summarised and meta-analysed the available literature that investigates the effects of diets containing fish oils or fish oil concentrates that have a high content of cetoleic acid but low or no content of epa and dha on cholesterol concentration in rodents, showing that cetoleic acid-rich fish oils and concentrates prevent high cholesterol concentration.


Eligibility criteria:
inclusion criteria: * bmi over 27 kg/m2 * stable body weight last 3 months exclusion criteria: * allergies towards fish, milk, egg, gluten * tobacco use (cigarettes or snus) * diseases affecting the heart, intestinal function, kidney function or insulin secretion * use of medications targeting cholesterol -or glucose metabolism, hypertension * use of dietary supplements * pregnant or breastfeeding * following a strict diet * had bariatric surgery * recent or planned surgical procedures * high intake of fish/seafood

Keywords: cholesterol cetoleic acid
assessing the safety, performance, and user experience of the tandem mobi automated insulin delivery system among young competitive athletes in real-world settings.

Conditions: Type 1 Diabetes

Summary: a single arm, interventional study with 12 weeks study phase preceded by a 2-week run in phase, aiming to evaluate the effectiveness and applicability of the tandem mobi automated insulin delivery system (tandem mobi pump system) for competitive youth athletes with type 1 diabetes in real-world conditions.


Eligibility criteria:
inclusion criteria: * type 1 diabetes (t1d) for at least 6 months * 11≤age≤18 years * hba1c \<10.0% * current treatment with automated insulin delivery system (aid) or insulin pump for at least 1 month * willing to switch to tandem mobi pump system and dexcom cgm for the study duration * competitive-level athletes exclusion criteria: * concomitant disease that influences metabolic control or hba1c interpretation * individual has any unresolved adverse skin condition in the area of sensor or device placement (e.g., psoriasis, rash, staphylococcus infection) * use of antidiabetic agents other than insulin * two or more episodes of severe hypoglycemia (hypoglycemia requiring treatment by another person) within the previous 6 months * one or more episodes of ketoacidosis requiring hospitalization within 6 months prior to screening * individual has a positive pregnancy screening test

Keywords: type 1 diabetes competitive athletes hybrid closed loop system
effects of probiotics on the patients with end stage renal disease (esrd)

Conditions: Kidney Failure, Chronic

Summary: the purpose of this study is to investigate the effects of oral administration of probiotics on the metabolism of uremic toxins, in the patients with end stage renal disease (esrd). one hundred and fifty hemodialysis patients are recruited, and a double blind randomized parallel controlled trial was performed.the microbiota-derived uremic toxin, such as indoxyl sulfate and p-cresol sulfate, are measured as primary outcome. the fecal microbiome, fecal metabolites, blood metabolites, defecation, gastrointestinal symptoms the kidney disease quality of life and the occurrence of cardiovascular event are also assessed.


Eligibility criteria:
inclusion criteria: * age over 18 years old * patients who diagnosed as esrd with hemodialysis * fixed hemodialysis cycle (average 3 times a week) * agree to take the products to be studied during the study period, and no longer take other fermented dairy products (live lactic acid bacteria drinks, cheese, yogurt, probiotic products, etc.) * agree to sign the informed consent form exclusion criteria: * taking antibiotics or antifungal drugs within 30 days before the study * have serious allergic reaction to skim milk powder * researcher are not sure whether the subjects are willing or able to complete the study * subject participated in other research projects within two months before the study

Keywords: kidney failure, chronic probiotics uremic toxins gastrointestinal microbiome
the influence of oral hygiene on local wound and systemic infection in patients with percutaneous endoscopic gastrostomy placement

Conditions: Dysphagia; Peristomal Wound Infection

Summary: percutaneous endoscopic gastrostomy (peg) is commonly used for long term enteral feeding of patients with severe dysphagia. the most common complication is peristomal wound infection. the possible mechanism the bacterial from the oral cavity disseminate during the peg insertion through the stomach to the abdominal wall, in spite the routine use of antibiotic prophylaxis, have reported low rates of wound infection in patients who were already receiving antibiotics at the time of peg our hypothesis that washing the oral cavity with antibiotic solution prior the insertion peg , we planned a prospective, randomised, double blind, one centre study of antibiotic mouth wash solution (0.2% chlorhexidine gluconate) as.prophylaxis in peg


Eligibility criteria:
inclusion criteria: * all patients scheduled to undergo peg exclusion criteria: * previous gi surgery * coagulopathy * sepsis

Keywords: percutaneous endoscopic gastrostomy peristomal wound infection antibiotic mouth wash solution prophylaxis prior percutaneous endoscopic gastrostomy (peg)
alpha lipoic acid to decrease pain and side effects in concurrent treatment of hnscc

Conditions: HNSCC

Summary: this is a phase i, single-center, non-randomized, 3+3 dose-escalation study of alpha lipoic acid given during chemotherapy-radiation in hnscc patients with non-metastatic disease.

the study will be completed when the mtd and rp2d are determined. this will be either when 2 or more patients have a dlt at a particular dose level, or when 6 patients have completed treatment at the highest dose level (600 mg tid). the final 3 patients enrolled at the highest tolerated dose will also complete pk studies.

Eligibility criteria:
inclusion criteria: 1. provision to sign and date the consent form. 2. stated willingness to comply with all study procedures and be available for the duration of the study. 3. be a male or female aged 18-100. 4. histologically or cytologically confirmed stage ii-ivb hnscc of the oral cavity, hypopharynx, oropharynx, larynx, or nasopharynx. 5. ability to take medication orally or per feeding tube and be willing to adhere to the medication regimen. 6. patients who are deemed appropriate for definitive, adjuvant, or palliative radiation with total planned dose \> 30 gy. 7. patients who are deemed appropriate for concurrent systemic therapy with radiation including cisplatin (100 mg/m2 triweekly or 30-40 mg/m2 weekly), carboplatin (auc 1-2 weekly) +/- paclitaxel (30 mg/m2 weekly) or cetuximab (400 mg/m2 loading followed by 250 mg/m2 weekly. a. the final 3 patients in the dose expansion group undergoing the pk/pd study must be deemed appropriate for cisplatin. 8. for females of reproductive potential: use of highly effective contraception including hormonal contraceptives, intrauterine devices (iud), vasectomy, tubal ligation, and double barrier methods (combination of male condom, female condom, cervical cap, diaphragm, contraceptive sponge). 9. for males of reproductive potential: use of condoms. 10. ecog performance status ≤ 2. exclusion criteria: 1. participation in another clinical study with an investigational product during the last 30 days. 2. concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study, a clinical study not involving pharmaceutical or radiation techniques, or during the follow-up period of an interventional study. 3. women who are pregnant or lactating. patients of reproductive potential must have a negative serum or urine pregnancy test within 72 hours of start of study drug. 4. patients who are currently taking gabapentin, pregabalin, amitriptyline, nortriptyline, or duloxetine. 5. known allergy or hyposensitivity to alpha lipoic acid. 6. judgement by the investigator that the patient is unsuitable to participate in the study and the patient in unlikely to comply with study procedures, restrictions, and requirements.